Search

7 Feb 2024: Do you have a developed business idea and are ready to take the next step? Are you looking to start a company...

20 Mar 2024: Amanda has spun out six new companies and worked on several follow-on funding rounds and exits.

6 Jun 2024: Mobile menu. Mobile menu. Search. back. back. back. back. back. Book your online session. Book your Technology Transfer session. To book a Technology Transfer session, you must fill out one of the corresponding forms below. Upon submission, you will

11 Mar 2024: Gillian Davis joined Cambridge Enterprise in 2009. She holds a BA in Natural Sciences from Oxford University and a doctorate in laser applications

29 Feb 2024: News and case studies. Pause. Play. Stay in touch with the latest updates on our international activities and programmes.

1 Aug 2023: Mobile menu. Mobile menu. Search. back. back. back. back. back. How we use your personal information – Cambridge Enterprise Venture Partners. How we use your personal information – Cambridge Enterprise Venture Partners. This policy is intended

21 May 2024: Software businesses evolve through relentless engagement with customers, understanding their new needs and spotting where the technical advantages of the software can deliver some distinctive performance. ... The new USIT Software Guide provides a common

7 May 2024: Patents – how something works (for example, a new material). Research reagents – materials produced in laboratory research (for example, model organisms, proteins, DNA/RNA, etc).

4 Jan 2024: High efficiency is achieved through our new heat integration technology using a multi-chamber system able to recover and deliver heat for the periodic, self-sufficient regeneration of the absorbent to

20 Mar 2024: During his employment, he was primarily entrusted with negotiating contracts and assessing intellectual property registrability of new projects. ... Helena has had extensive involvement with the development and implementation of the new CRM system.

20 Mar 2024: Christine Martin overseas our investment activities, with the team investing over £5 million each year in young companies.

4 Jan 2024: Low-loss high-speed data transmission. Professor Mike Payne and his research team have developed a new data transmission design, based on a pair of Goubau Lines – metallic tracks or wires ... By using an appropriate antenna as a launcher and tailoring

11 Jun 2024: 11 June 2024. Lab-grown ‘mini-guts’ could help in development of new and more personalised treatments for Crohn’s disease. ... The researchers say the organoids could be used to develop and test new treatments, to see how effective they are on the

6 Jun 2024: We support social ventures originating from the University of Cambridge at every stage, from the initial idea to investment and beyond.

12 Dec 2023: Subscription Preferences. We collect information about you when you opt-in to receive communications from us in connection with topics you have selected, such as news and/or events.

10 Aug 2023: Co-founded by Dr Tongtong Zhu (CEO), Dr Yingjun Liu (CTO) and Professor Rachel Oliver (CSO), Porotech had hit upon and developed a new class of porous gallium nitride (GaN) semiconductor ... This latest funding will accelerate our work to ensure that

6 Mar 2024: Mobile menu. Mobile menu. Search. back. back. back. back. back. CRoSS. What is Cambridge CRoSS? CRoSS (Commercialisation of Research out of Social Sciences) is an ESRC-seeded impact acceleration programme designed to engage social innovators from

20 Mar 2024: In 2017-18, Amanda’s team saw a 63% increase in the number of new consultants with deals signed for 165 academics and 234 clients in that period. ... During this time, he advised businesses from early-stage translational companies to global

1 Feb 2024: Ananay oversees the activities of TenU, an international collaboration of leading tech transfer offices created to share effective practices in research commercialisation...

4 Jan 2024: In 2020, there were 1.9 million new cases of colorectal cancer, which is the 3rd most common cancer worldwide. ... As a therapeutic target, LGR5 is relatively new but has been validated in a range of cancers with a therapeutic window of expression.